Maidstone, England-based Bedfont designed its NObreath fractional exhaled nitric oxide (FeNO) monitoring system as a portable, non-invasive device for measuring FeNO in the human breath. Inflammatory conditions like asthma can often increase production of nitric oxide.
According to a news release, NObreath works by measuring FeNO through breath analysis in a quick, simple and non-invasive process. Measuring FeNO levels allows for identifying patients who do or do not require ongoing treatment. It can also differentiate between allergic and non-allergic asthma, and daily use can help predict and prevent exacerbations and attacks, Bedfont said.
“NObreath has been available outside the US for over 12 years now, we have been working towards FDA clearance for quite some time, and we are over the moon to have received it,” Bedfont Managing Director Jason Smith said in the release. “We are one step closer to achieving our purpose; to make FeNO monitoring lower cost and therefore more accessible globally.”
